The Food and Drug Administration's Pharmacy Compounding Advisory Committee convened Friday for the second day of a two-day meeting to consider whether to ease restrictions on peptides, compounds popular among wellness influencers and celebrities but whose safety and effectiveness remain scientifically unproven.
Day 2 of the panel is scheduled to begin at 8 a.m. EDT with votes on seven popular peptide compounds expected later in the session. The gathering has attracted significant attention given its backing from Health Secretary Robert F. Kennedy Jr., who has described himself as a "big fan" of peptides and vowed to overturn restrictions put in place under President Joe Biden.
The meeting marks a rare public forum where the FDA is being asked to broaden access to compounds that have proliferated through social media platforms, often promoted by wellness advocates claiming benefits for muscle building, injury recovery and anti-aging.
What the Left Is Saying
Democratic lawmakers and public health advocates argue that loosening compounding pharmacy rules could expose patients to unregulated substances without adequate scientific vetting. They point to FDA career scientists who have consistently maintained there is insufficient clinical evidence to support wider peptide availability.
Representative Jamie Raskin of Maryland said the panel's proceedings raise concerns about regulatory capture. "The American people deserve a FDA that follows science, not one that bends to political pressure from wellness influencers with financial stakes in these products," Raskin wrote on social media.
Organizations including the Institute for Safe Medication Practices have urged caution. President Rita Jew, a pharmacist, told reporters ahead of the meeting: "There aren't that many other substances people are injecting into themselves where you see that the clinical evidence is so lacking."
Progressive health policy advocates warn that easing compounding rules could undermine the FDA's drug approval process, which requires rigorous clinical trials before new medications reach consumers.
What the Right Is Saying
Supporters of expanded peptide access argue that current restrictions prevent patients from obtaining treatments they believe improve their quality of life. They contend that compounding pharmacies offer a legitimate alternative when commercially manufactured drugs are unavailable or unsuitable for individual patients.
Health Secretary Kennedy has championed the issue as part of his broader "Make America Healthy Again" agenda, arguing that federal regulators have been too restrictive in limiting consumer access to wellness products. The committee's meeting was convened at his urging.
Wellness advocates including podcaster Joe Rogan and influencer Gary Brecka, who sells peptide products online and supports Kennedy's initiative, argue that thousands of Americans report personal benefits from peptide use that mainstream medicine ignores. "People deserve the right to make informed choices about their own health," Brecka said in a video post with millions of views.
Conservative commentators have framed the debate as a question of regulatory overreach, arguing that adults should be able to access compounds their doctors prescribe without excessive federal interference.
What the Numbers Show
On Thursday, the panel narrowly voted to recommend easing access to several peptide compounds on its agenda, though specific vote counts had not been released by press time. The votes are advisory only and do not bind the FDA to any action.
The 20-member advisory committee includes at least seven doctors or pharmacists with documented financial ties to the peptide industry, including owners of wellness clinics that sell peptides, pharmacies that produce them and online consulting businesses that promote their use.
FDA officials confirmed earlier this week that they added several academic experts without industry connections to strengthen scientific representation on the panel. The agency has periodically gone against recommendations from its outside advisory committees in past proceedings.
Peptides are short chains of amino acids that can be manufactured as injectable compounds. Unlike FDA-approved drugs, compounded peptides have not undergone large-scale clinical trials demonstrating safety and efficacy for their marketed uses.
The Bottom Line
The committee's votes on the seven peptide compounds will signal whether there is sufficient scientific consensus to expand compounding pharmacy access, but the final decision rests with FDA career leadership and political appointees. Health Secretary Kennedy has indicated he intends to pursue regulatory changes regardless of the panel's recommendations.
The meeting highlights a broader tension between personalized wellness culture and evidence-based medicine regulation. Consumer advocates on both sides are watching closely as the administration signals willingness to reshape pharmaceutical oversight.
The FDA is expected to issue a formal response to the committee's recommendations within weeks. Any regulatory changes affecting compounding pharmacies could affect millions of patients who obtain customized medications through these facilities annually.